<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[mg Magazine - Medium]]></title>
        <description><![CDATA[mg Magazine is the leading trade journal for the US cannabis industry. Since 2015 it has provided readers with the news, market trends, and intelligence necessary to make informed business decisions. - Medium]]></description>
        <link>https://medium.com/mg-magazine?source=rss----a3e9cdb23cde---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>mg Magazine - Medium</title>
            <link>https://medium.com/mg-magazine?source=rss----a3e9cdb23cde---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 05:07:31 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/mg-magazine" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[What’s Driving Demand for Premium Cannabis Concentrates?]]></title>
            <link>https://medium.com/mg-magazine/whats-driving-demand-for-premium-cannabis-concentrates-68d72235fe00?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/68d72235fe00</guid>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <category><![CDATA[cannabis-legalization]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Tue, 14 Jul 2026 21:43:07 GMT</pubDate>
            <atom:updated>2026-07-14T21:43:06.942Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*FJKCH1Sk3U39Kawe.jpg" /><figcaption><em>Premium concentrate buyers increasingly expect retail staff to explain extraction methods, terpene profiles, testing data, and product differences. (Image: mg Creative)</em></figcaption></figure><p>The question retailers hear most often has changed. It used to be “what has the most THC?” Now it’s more likely to be “how was this made?” or “can I see the COA?” (COA is an acronym for “certificate of analysis.”) That shift — from potency chasing to process awareness — is the most accurate measure of where the cannabis consumer actually is in 2026, and it’s reshaping the concentrate category in ways that raw market data alone doesn’t fully capture.</p><h3>Rosin’s growth sends a signal</h3><p>Concentrates have moved from a niche enthusiast category toward the cannabis mainstream, but the growth isn’t uniform. The segment that’s actually outperforming is narrow and specific: Rosin, a labor-intensive, craft-oriented, solventless product, <a href="https://www.cannabissciencetech.com/view/2025-state-of-the-cannabis-industry-sales-trends-and-forecasts">grew 8.1 percent</a> in year-over-year sales in an extract market that is otherwise largely flat to declining, according to BDSA. The same report shows the number of rosin products on the market expanded 11 percent, and average retail price held at $31 per gram — a significant premium that consumers are demonstrably willing to pay. In a market defined by persistent price compression, that’s a meaningful signal.</p><p>What it signals is the demand driving concentrate growth isn’t primarily about getting higher. It’s about knowing more.</p><p>Understanding that requires some grounding in what concentrates are and how the categories differ.</p><h3>How concentrate categories differ</h3><p>The three main categories reflect meaningfully different production approaches. <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/solventless-concentrates-are-worth-their-weight-in-gold/"><strong>Solventless products</strong></a> — rosin, bubble hash, hash rosin — are produced without hydrocarbon or alcohol-based extraction solvents, using combinations of ice water, heat, pressure, and mechanical separation. These products often carry a “cleaner” perception and command premium pricing. <strong>Solvent-based concentrates</strong>, including live resin, wax, badder, and shatter, use food-grade hydrocarbon solvents that are purged from the finished product; these are commonly used in infused pre-rolls and many vape formulations. At the far end of the refinement spectrum, <strong>crystalline and high-purity concentrates</strong> — diamonds, isolate, diamonds-and-sauce — strip most other plant compounds away to reach purity levels approaching 99 percent.</p><h3>Consumers are asking better questions</h3><p>Each category delivers a different expression of the plant, and each appeals to a different consumer at a different price point.</p><p>For retailers, the significance of those distinctions has grown considerably. Two years ago, most concentrate conversations on the sales floor started and ended with potency. Today, they’re more likely to involve <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/which-is-the-better-extraction-method-solvent-or-solventless/">extraction method</a>, terpene profile, and whether a COA is available for the specific batch. That’s not a marginal shift. It’s a fundamental change in what the consumer expects to know before purchasing.</p><h3>Market data points toward premium demand</h3><p>The broader market data provides useful context. The global cannabis concentrate market was valued at $1.6 billion in 2025 and is <a href="https://www.accessnewswire.com/newsroom/en/business-and-professional-services/cannabis-concentrate-market-projected-to-reach-usd-6.8-billion-b-1139490">projected to reach $6.8 billion by 2035</a> at a 15.7 percent compound annual growth rate (CAGR), according to Future Market Insights. Fortune Business Insights placed the broader cannabis extract category — which includes vapes, edibles, tinctures, and other extract-based formats — at <a href="https://www.fortunebusinessinsights.com/cannabis-extract-market-114500#">$16.4 billion in 2025</a>. Vapes and cartridges currently hold the largest product share at 47.5 percent of the global market, driven by convenience and bioavailability. Full-spectrum extracts lead the extract type segment with a 60.74-percent share, suggesting strong consumer interest in formulations that preserve a broader range of plant compounds.</p><p>That full-spectrum preference may reflect the same instinct driving rosin’s growth. Consumers aren’t just moving toward concentrates; they’re moving toward concentrates that preserve more of the plant, not less. The indica/sativa/hybrid framework is losing its organizing power on the retail floor as consumers increasingly focus on terpene profiles and the specific characteristics that shape effects. That’s a more sophisticated purchasing framework, and it requires a more sophisticated retail conversation.</p><h3>Training turns product knowledge into retail value</h3><p>That is why training is now critical infrastructure. The consumer who wants to understand the difference between live resin and rosin before purchasing, who expects to be able to scan a QR code for batch-specific lab results, who is asking about terpene retention rather than THC percentage — that consumer requires frontline staff who can meet them at their level of knowledge. Transparency is no longer a differentiator; it’s a baseline expectation. Brands that provide accessible COAs, clear sourcing information, and honest comparative product data are earning trust in a market where, historically, claims have outrun reality.</p><p>The implication for retail isn’t complicated, but it does require intention. Training programs that still center the conversation on THC percentages are preparing staff for a purchasing dynamic that’s already shifting. The consumers who are driving growth in the premium concentrate segment want to understand what they’re buying: <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/solventless-extraction-optimization/">the process</a>, the plant, the data behind the label. Retailers who can deliver that conversation are better positioned to capture and retain those buyers.</p><p>Concentrates won’t displace flower, which remains the market’s foundation. But the premium concentrate segment is demonstrating something worth paying attention to: In a mature market under price pressure, the product categories with the most resilience aren’t the cheapest or the most potent. They’re the ones with the most to explain — and retailers who can explain them well are the ones with the most to gain.</p><p>By <a href="https://mgmagazine.com/author/tripp-liles/"><strong>Tripp Liles</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/premium-cannabis-concentrates-retail-demand/">https://mgmagazine.com/retail-brands/retailing-merchandising/premium-cannabis-concentrates-retail-demand/</a> on July 14th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=68d72235fe00" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/whats-driving-demand-for-premium-cannabis-concentrates-68d72235fe00">What’s Driving Demand for Premium Cannabis Concentrates?</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[After 280E, Cannabis CFOs Need a Capital Plan]]></title>
            <link>https://medium.com/mg-magazine/after-280e-cannabis-cfos-need-a-capital-plan-b750d4a73778?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/b750d4a73778</guid>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[irc]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Wed, 01 Jul 2026 22:29:35 GMT</pubDate>
            <atom:updated>2026-07-01T22:29:35.359Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*5DkzZRal6PUygPs8.jpg" /><figcaption><em>Potential 280E relief could give cannabis finance leaders more flexibility to fund equipment, systems, and operational improvements. (Image: mg Creative)</em></figcaption></figure><p>For years, conversations around cannabis rescheduling have centered on one issue: the potential elimination of Internal Revenue Code (IRC) Section 280E and the crushing tax burden it places on operators. While that discussion is important, chief financial officers (CFOs) and finance leaders should be looking beyond tax relief alone as rescheduling finally becomes more tangible.</p><p>The larger story is what improved cash flow could enable operationally. If cannabis is moved to Schedule III, the industry may experience one of the most significant financial shifts in its history — one that fundamentally changes capital allocation, profitability strategies, and long-term investment planning. Schedule III is not simply a tax event. It is a financial restructuring opportunity.</p><h3>The consequences of financial constraint</h3><p>For decades, cannabis businesses have operated under financial conditions unlike those faced by almost any other legal industry. Because of 280E’s prohibition on deducting ordinary operating expenses, many businesses have faced effective combined state and local tax rates <a href="https://mgmagazine.com/press-releases/whitney-economics-cannabis-businesses-paid-2-24b-in-excess-2025-taxes-due-to-280e/">as high as 70 percent</a>.</p><p>The result has been chronic cash flow pressure even among companies generating significant revenue. Many operators have delayed equipment purchases, postponed facility upgrades, and underinvested in automation simply because capital was unavailable after taxes were paid. In many cases, businesses have accepted operational inefficiencies that would be unacceptable in other industries because survival took priority over optimization.</p><p>These constraints have distorted financial decision-making throughout the industry. Rather than investing strategically for growth, operators often have focused on short-term liquidity management and tax mitigation. Scaling operations while maintaining compliance has become increasingly difficult, particularly as markets mature and margins tighten.</p><h3>The first task is scenario planning</h3><p>The elimination of 280E would improve net profitability immediately for many cannabis businesses by allowing them to deduct ordinary business expenses like virtually every other legal industry.</p><p>More importantly, a release from the tax burden would transform cash flow. Retained earnings that previously were consumed by taxes could be redirected into the business. Improved liquidity would strengthen working-capital management, enhance budgeting flexibility, and create greater predictability in financial forecasting.</p><p>For CFOs, this shift represents an opportunity to move from defensive financial management toward proactive growth planning. Resources currently dedicated to managing tax burdens instead could support expansion initiatives, operational improvements, and investments that create long-term enterprise value.</p><p>The most successful operators will not simply celebrate improved profitability. They will develop deliberate strategies for deploying newly available capital in ways that strengthen competitive positioning before the market becomes even more crowded.</p><h3>Existing tax tools could become more useful</h3><p>While the <a href="https://mgmagazine.com/policy-regulation/cannabis-rescheduling-280e-tax-preparation/">elimination of 280E</a> has received the majority of attention, several additional tax benefits could prove equally important.</p><p>Deductions under IRC Section 179 could allow operators to immediately expense qualifying equipment purchases rather than depreciating them over multiple years. That could make investments in extraction systems, packaging equipment, environmental controls, HVAC systems, and post-harvest processing technologies significantly more attractive from a financial standpoint.</p><p>Bonus depreciation and accelerated depreciation opportunities may also improve return-on-investment calculations for capital projects. Faster recovery of capital expenditures can shorten payback periods, improve project economics and justify investments that previously may have been deferred.</p><p>Perhaps most important, cannabis businesses would gain the ability to engage in more sophisticated tax planning strategies commonly utilized by mainstream manufacturers and consumer packaged goods companies. Financial planning could become focused on optimizing growth rather than navigating regulatory tax disadvantages.</p><p>At the same time, broader financial normalization may begin attracting traditional lenders, <a href="https://mgmagazine.com/business-strategy/finance-acquisitions-business-strategy/eliminating-280e-could-spark-an-investment-frenzy/">institutional capital providers</a>, and commercial financing partners. Access to more conventional lending products and lower interest rates could substantially reduce the cost of capital for operators. Combined with improved tax treatment, lower financing costs could dramatically improve project feasibility and accelerate investment throughout the industry.</p><h3>Preparing for a more competitive industry</h3><p>Rescheduling will create opportunities not only for existing operators but also may attract new entrants, additional investment capital and increased competition.</p><p>Both potentialities make preparation critical. The strongest operators will use this transition period strategically, reinvesting in facilities, systems, and infrastructure before competitive pressures intensify. They will strengthen balance sheets, improve operational efficiency and build scalable business models capable of supporting long-term growth. For many finance leaders, this represents a fundamental shift from reactive cash management toward strategic capital planning. The organizations that prepare now will be better positioned to capitalize on future opportunities.</p><h3>The financial rewards of operational evolution</h3><p>As cannabis continues to mature, operators increasingly must function like sophisticated manufacturing and consumer packaged goods organizations. That evolution requires investment.</p><p>Automation technologies can help optimize labor utilization, improve throughput and reduce production variability. Infrastructure upgrades can improve energy efficiency, enhance environmental controls and create more scalable cultivation and manufacturing environments.</p><p>Compliance and quality systems are equally important. Investments in track-and-trace platforms, data-management systems, testing protocols, quality-assurance programs, and post-harvest technologies can improve consistency, strengthen regulatory readiness, and protect product integrity throughout the supply chain. The operators that thrive in a post-Schedule III environment will be those that use newfound financial flexibility to build stronger, more efficient organizations.</p><h3>Strategic recommendations for cannabis CFOs</h3><p>Finance leaders should begin with five practical steps:</p><ol><li><strong>Model multiple tax and cash-flow scenarios.</strong> Understand how tax changes could impact profitability, cash flow, and available capital. Comparing current-state financial performance against potential post-rescheduling outcomes can help identify areas where reinvestment may generate the strongest returns.</li><li><strong>Re-rank deferred projects.</strong> Reevaluate equipment, systems, facility, and automation investments that previously were unattractive under 280E economics.</li><li><strong>Define capital-allocation priorities.</strong> Decide in advance how released cash will be divided among debt reduction, reserves, maintenance, growth investments, and owner distributions to balance growth investments with liquidity preservation and financial stability.</li><li><strong>Review tax and depreciation strategy.</strong> Work with qualified advisors to prepare for new deduction and depreciation opportunities.</li><li><strong>Prepare a lender and investor narrative.</strong> Update forecasts and supporting materials so prospective capital partners can see how the company plans to use improved liquidity to create durable enterprise value.</li></ol><h3>The real opportunity is operational discipline</h3><p>If the entirety of the cannabis industry moves to Schedule III, it could reshape the financial future. The end of 280E may be the headline, but it is only the beginning of the story. The real opportunity lies in <a href="https://mgmagazine.com/business-strategy/finance-acquisitions-business-strategy/post-280e-market-playbook/">how operators choose to deploy the capital</a> that becomes available as a result.</p><p>For CFOs, Schedule III should not be viewed simply as tax reform. It should be viewed as a catalyst for transformation that builds stronger, more profitable, and more resilient cannabis businesses for the future.</p><p>By <a href="https://mgmagazine.com/author/spencer-newman/"><strong>Spencer Newman</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/business-strategy/finance-acquisitions-business-strategy/schedule-iii-cannabis-cfo-tax-planning/">https://mgmagazine.com/business-strategy/finance-acquisitions-business-strategy/schedule-iii-cannabis-cfo-tax-planning/</a> on June 30th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b750d4a73778" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/after-280e-cannabis-cfos-need-a-capital-plan-b750d4a73778">After 280E, Cannabis CFOs Need a Capital Plan</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Is Your Medical Cannabis Operation Ready for DEA Registration?]]></title>
            <link>https://medium.com/mg-magazine/is-your-medical-cannabis-operation-ready-for-dea-registration-b40e6d535eb6?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/b40e6d535eb6</guid>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabis-legalization]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Tue, 23 Jun 2026 23:07:07 GMT</pubDate>
            <atom:updated>2026-06-23T23:07:07.446Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*Ms_0Hv63BqY6ZdFd.jpg" /><figcaption><em>Medical cannabis operators preparing for DEA registration should be able to document facility security, inventory controls, records management, and operating procedures. (Image: mg Creative / DALL-E)</em></figcaption></figure><p>As the cannabis industry focuses on the federal <a href="https://mgmagazine.com/policy-regulation/dea-rescheduling-hearing-roster/">rescheduling hearings slated to begin June 29</a>, many medical cannabis operators are overlooking a countdown happening three days prior. This deadline could quietly dictate their future competitiveness.</p><p>Medical cannabis businesses have a narrow window to <a href="https://mgmagazine.com/policy-regulation/medical-cannabis-dea-registration-deadline/">register with the Drug Enforcement Administration</a> (DEA) to qualify for expedited review as federal agencies evaluate the transition to Schedule III. That window closes June 26. While the macro-level policy debate captures headlines, operators need to look at what federal preparedness looks like in practice.</p><p>For medical cannabis businesses, early action is about far more than compliance. It is about strategic positioning.</p><h3>DEA registration is a time-sensitive filing, not a routine administrative task</h3><p>One of the biggest misconceptions among operators is that obtaining a DEA registration will be a straightforward administrative process. In reality, federal registration functions much more like a comprehensive audit.</p><p>Many operators have spent years building compliance programs designed to satisfy state regulators. The new registration pathway does not erase the value of state compliance systems, but it does make their consistency, accessibility, and scope more consequential. The DEA will not show up empty-handed, and operators cannot afford to, either.</p><p>Before applying, operators should evaluate whether they can readily produce documentation such as:</p><ul><li>Corporate ownership disclosures and organizational records.</li><li>Facility blueprints and floor plans.</li><li>Zoning documentation and local approvals.</li><li>Security infrastructure and surveillance protocols.</li><li>Inventory control and chain-of-custody procedures.</li><li>Employee training and compliance records.</li></ul><p>In our experience advising cannabis businesses across multiple jurisdictions, many organizations discover significant documentation gaps when measured against anticipated federal expectations.</p><h3>Turn SOPs and traceability into a readiness test</h3><p>As cannabis moves toward a Schedule III framework, <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/dispensary-loss-prevention-sops/">standard operating procedures (SOPs)</a> will become an operator’s ultimate line of defense.</p><p>Federal regulators are not simply evaluating whether a business possesses the proper paperwork. They are evaluating whether an organization can manage a controlled substance safely. Strong SOPs demonstrate operational consistency, accountability, and risk management.</p><p>Areas that deserve particular attention include:</p><h3>Diversion prevention</h3><p>Operators must have airtight, documented procedures that ensure cannabis products remain strictly within authorized, legal channels at every stage of cultivation, processing, storage, and distribution.</p><h3>Inventory segregation</h3><p>For businesses operating in both medical and adult-use markets, the ability to separate product streams will be vital under a federal framework. We are already seeing this play out at the state level. Markets like California increasingly are forcing dual-licensed operators to separate medical and adult-use workflows. Clear inventory controls help demonstrate compliance while reducing regulatory risk.</p><h3>Recordkeeping and traceability</h3><p>Federal oversight places an immense premium on record retention, accessibility, and chain-of-custody documentation. Operators must be prepared to retrieve records quickly and maintain clear, verifiable audit trails. A useful readiness test is whether the team can retrieve complete, credible records promptly during an inspection or diligence review.</p><p>The operational reality: If your team cannot retrieve detailed, compliant chain-of-custody data within minutes during an inspection, you are not federally prepared.</p><h3>Compliance is becoming a competitive advantage</h3><p>Historically, compliance often has been viewed as a cost center. As federal reform progresses, that mindset may need to shift.</p><p>Investors, lenders, strategic partners, and potential acquirers increasingly view compliance infrastructure as the ultimate indicator of organizational maturity. Businesses that establish robust systems now will find themselves better positioned to access traditional capital, pursue expansion opportunities, and attract strategic partnerships.</p><p>The financial implications could be substantial. The potential ability to move beyond Internal Revenue Code Section 280E restrictions under a <a href="https://mgmagazine.com/policy-regulation/cannabis-schedule-iii-impact-280e-analysis/">Schedule III framework</a> has created significant interest among operators seeking to improve profitability and valuation. <a href="https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products">The Blanche rule</a> says holders of qualifying state medical licenses are no longer subject to 280E, but individual tax treatment still deserves counsel review.</p><p>Organizations that prepare early may be better positioned to capitalize on those opportunities as regulatory frameworks evolve.</p><h3>The window for preparation is narrowing</h3><p>Whether federal reform ultimately moves quickly or gradually, one reality that is becoming increasingly clear is the operators who invest in operational readiness today are the ones who will lead the market tomorrow.</p><p>The June 26 registration deadline represents more than an administrative milestone. It is an opportunity for medical cannabis businesses to honestly assess their compliance infrastructure, identify their operational gaps, and protect their hard-earned licenses.</p><p>For operators, the question is no longer whether federal oversight is coming. The question is whether your organization will be ready when it arrives.</p><p>By <a href="https://mgmagazine.com/author/sara-gullickson/"><strong>Sara Gullickson</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/policy-regulation/medical-cannabis-dea-readiness/">https://mgmagazine.com/policy-regulation/medical-cannabis-dea-readiness/</a> on June 23rd, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b40e6d535eb6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/is-your-medical-cannabis-operation-ready-for-dea-registration-b40e6d535eb6">Is Your Medical Cannabis Operation Ready for DEA Registration?</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Medical Cannabis Operators Face June 26 DEA Registration Deadline]]></title>
            <link>https://medium.com/mg-magazine/medical-cannabis-operators-face-june-26-dea-registration-deadline-97d0881cd0ee?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/97d0881cd0ee</guid>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[dea]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Fri, 19 Jun 2026 21:17:07 GMT</pubDate>
            <atom:updated>2026-06-19T21:17:07.163Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*8tlgeTNIWkQa_DWL.png" /></figure><p>The clock is ticking. On April 28, the <a href="https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products">Blanche rescheduling order</a> took effect, moving state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). That change was significant. So was what it triggered: a mandatory Drug Enforcement Administration registration requirement for every state-licensed medical cannabis entity that manufactures, cultivates, processes, distributes, or dispenses medical marijuana or medical marijuana products.</p><p>The DEA opened a 60-day expedited registration window when the rule took effect April 28. Because the 60th day falls on Saturday, June 27, operators should treat <strong>Friday, June 26</strong>, as the effective business deadline — and for most applicants, the practical deadline is sooner.</p><h3>What the Blanche order changed</h3><p>The reclassification to Schedule III means federal law no longer treats state-licensed <em>medical</em> cannabis as a substance with no accepted medical use and high abuse potential. It is now in the same category as anabolic steroids and ketamine — still a controlled substance, but not controlled to the point of prohibition. That is meaningful progress.</p><p>However, adult-use cannabis remains on Schedule I, in the same category with illegal drugs including heroin and LSD. The Blanche order covers only <strong>state-licensed medical cannabis</strong> and cannabis products approved by the Food and Drug Administration. Operators who handle both medical and adult-use must segregate their operations clearly and precisely, and the DEA registration requirement applies only to the medical side.</p><p>This distinction is not academic. An operator who conflates medical and adult-use inventory in their DEA registration filing is creating a federal compliance exposure, not resolving one.</p><h3>Who needs a DEA registration</h3><p>The registration requirement covers the full medical cannabis supply chain.</p><p>• <strong>Cultivators and manufacturers</strong>: entities growing or producing state-licensed medical cannabis plants or products.</p><p>• <strong>Distributors</strong>: entities moving medical cannabis between licensed facilities.</p><p>• <strong>Dispensaries</strong>: retail-facing entities dispensing medical cannabis to patients.</p><p>If your operation “handles” state-licensed medical cannabis products at any point in the supply chain, you need a DEA registration.</p><p>Operators who already hold DEA registrations — pharmacies, pharmaceutical manufacturers — should confirm with counsel whether their existing registration is sufficient or whether an amended or new registration for cannabis-specific Schedule III handling is required. Do not assume an existing registration covers this.</p><h3>How to file a DEA registration application</h3><p>Dispensary applicants should use DEA’s <a href="https://mmapplication.diversion.dea.gov/">Medical Marijuana Dispensary Registration Portal</a>; other applicants should follow <a href="https://deadiversion.usdoj.gov/">DEA Diversion registration</a> instructions for their activity type. Each dispensary application requires a nonrefundable fee of $794.</p><p>The application may be especially onerous for dispensaries, because DEA asks applicants to provide <a href="https://mmapplication.diversion.dea.gov/registration-instructions">identifying information for all individuals</a> anticipated to “have access to controlled substances,” including names, titles, dates of birth, Social Security numbers, and applicable DEA or state license numbers.</p><p>Required documentation typically includes a state license, business entity information, and a description of the controlled substance handling activity. Confirm specific documentation requirements in the DEA’s diversion portal or through legal counsel.</p><h3>What happens if you miss the deadline?</h3><p>This is where operators need to understand the stakes clearly.</p><p>Existing licensed operators who miss the deadline lose the rule’s pending-application protection. That’s important, because the Rohrabacher-Blumenauer budget rider was omitted from the “<a href="https://www.congress.gov/bill/119th-congress/house-bill/1/text">One Big Beautiful Bill Act</a>” federal budget package signed into law July 4, 2025. Since 2014, Rohrabacher-Blumenauer (formerly known as Rohrabacher-Farr) had barred the Department of Justice from using federal funds to interfere with state medical cannabis programs. The status of Rohrabacher-Blumenauer protections is no longer a clean fallback, and operators should not treat annual appropriations language as a substitute for CSA compliance.</p><p>Consequently, operators need to be aware:</p><p>1. Operating without DEA registration while handling Schedule III cannabis becomes a <strong>federal violation</strong>.</p><p>2. <strong>Civil penalties may apply</strong>, including fines of up to $25,000 per violation for certain CSA violations, depending on the conduct.</p><p>3. <strong>Criminal exposure is possible</strong> for unauthorized handling of a Schedule III substance.</p><p>4. <strong>DEA may limit or deny</strong> future registration eligibility for existing state-licensed operators who fail to register before the June 26 deadline.</p><p>Legal challenges to the Blanche order pending in the U.S. Court of Appeals for the D.C. Circuit do not change this calculus. As of publication, no stay of the order appears to have been granted. The order remains in effect unless and until a court says otherwise.</p><h3>Why registration strengthens compliance posture</h3><p>For decades, the cannabis industry has operated under federal legal tolerance, not federal legal standing. Medical operators who register with the DEA will have a clearer federal compliance posture under the CSA than they had under Schedule I, but registration does not legalize adult-use activity or eliminate all federal risk.</p><p>The registration window is a compliance requirement. It is also an opportunity to gain a level of operational security cannabis businesses have not experienced previously.</p><h3>Action steps before the deadline</h3><ol><li><strong>Gather</strong> your state license(s) and other required business documentation.</li><li><strong>File</strong> at<a href="https://deadiversion.usdoj.gov/"> <strong>deadiversion.usdoj.gov</strong></a> before the deadline.</li><li><strong>Target</strong> submission by <strong>June 22–25</strong> — do not wait until June 26.</li></ol><p>The window closes in days, not weeks.</p><p>By <a href="https://mgmagazine.com/author/nora-whitfield/"><strong>Nora Whitfield</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/business-strategy/operations-supply-chain/medical-cannabis-dea-registration-deadline/">https://mgmagazine.com/business-strategy/operations-supply-chain/medical-cannabis-dea-registration-deadline/</a> on June 18th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=97d0881cd0ee" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/medical-cannabis-operators-face-june-26-dea-registration-deadline-97d0881cd0ee">Medical Cannabis Operators Face June 26 DEA Registration Deadline</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Stale Flower Is a Margin Killer]]></title>
            <link>https://medium.com/mg-magazine/stale-flower-is-a-margin-killer-90b86c92fdcd?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/90b86c92fdcd</guid>
            <category><![CDATA[cannabis-journalism]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[retail]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Mon, 01 Jun 2026 22:57:45 GMT</pubDate>
            <atom:updated>2026-06-01T22:57:45.433Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*ohxAabwmpFzY7HoT.jpg" /><figcaption><em>Image: mg Creative</em></figcaption></figure><p>Flower loses value long before it becomes unsellable. As package dates age, terpene expression changes, moisture content drifts, velocity slows, and managers reach for discounts. In a compressed market, that sequence can turn a profitable category into a slow leak that damages dispensary profit margins.For dispensary owners and inventory managers, stale flower creates a problem that is both operational and financial. A fresh eighth already competes in a market shaped by aggressive pricing, frequent promotions, and shoppers trained to look for value. An old eighth faces all of that pressure plus a product-specific handicap. The package date becomes a silent objection, and the most common fix is a markdown.</p><p>That is why freshness should not be treated as a back-office detail. It should be evaluated and accounted for alongside sales, labor, cash, compliance, and shrink.</p><h3>Borrow from the produce aisle</h3><p>Grocery retailers have managed this problem for decades in produce departments, where the product is perishable, quality is visible, shrink is expected, and timing determines margin. The best operators do not wait until lettuce wilts or berries soften before acting. They manage the category through disciplined receiving, cold-chain control, rotation, shrink tracking, and promotions timed to protect velocity before quality declines.</p><p>Flower is not produce, but the retail levers are similar. Both categories reward operators who understand the remaining selling window. Both punish overbuying. Both require storage discipline. Both depend on staff execution. And both can turn from premium inventory into discounted inventory when buyers miss the timing.</p><p>For dispensaries, the lesson is to start treating freshness as an operating variable that can be managed well before it becomes a margin problem.</p><h3>Stale inventory has a carrying cost</h3><p>Every unsold unit ties up cash, occupies shelf space, and absorbs labor. In flower, those costs are amplified by a product whose value depends on maintaining quality from harvest through sale. The longer product sits, the fewer options remain available for protecting margin.</p><p>Recent research reinforced what operators already know from experience: Drying and storage conditions matter. A study published in <em>Analytical and Bioanalytical Chemistry</em> found postharvest handling and storage can affect aroma compounds and cannabinoid profiles, both of which contribute to marketability and perceived quality.</p><p>That does not mean buyers should treat older product as defective. It should be a flag indicating more attention is needed before inventory becomes a sales problem.</p><h3>Freshness is becoming a compliance issue</h3><p>Regulators also are beginning to formalize freshness expectations. Colorado requires use-by dates for inhaled products, including flower, shake, trim, and pre-rolls. The state caps those dates at no more than nine months from harvest or production unless shelf-stability testing supports a longer period. Cannabis retail operations also must inform patients or consumers when a product is past its use-by date.</p><p>This applies to all retailers, regardless of location. While the rules may vary by state, the direction is clear: Package age, storage conditions, and product stability are now visible parts of the retail conversation.</p><p>Water activity offers another practical benchmark. <a href="https://www.astm.org/d8197-21.html">ASTM International’s D8197 standard</a> identifies 0.55 to 0.65 aw as the recommended range for dry cannabis flower. The range is useful not only as a quality-control measure but also as a purchasing and receiving standard. Flower that falls outside expected parameters may create downstream problems in handling, consumer experience, sell-through, and markdown exposure.</p><h3>Build freshness into procurement</h3><p>A productive program starts well in advance of the product reaching the sales floor. Buyers should adhere to a disciplined process and require suppliers to provide the harvest date, package date, test date, certificate-of-analysis access, and water-activity data when available. Intake standards should define the oldest acceptable package date by category and price tier.</p><p>This is where bargain buying can become expensive. A discounted wholesale lot may look attractive on paper, but if the store has to discount it again to create velocity, the buy may erode margin instead of improving it. The better question is not “How cheap is it?” but “How much full-margin selling time remains?”</p><blockquote><strong>Freshness is not just a merchandising promise. It is a margin discipline.</strong></blockquote><p>Vendors need to be held accountable to the same disciplined process. Brands that want shelf space should be able to provide product age, storage conditions, batch consistency, expected sell-through, and promotional support. Growers, manufacturers, distributors, and retailers share responsibility for maximizing the commercial life of the product at every stage.</p><h3>Manage exceptions, not reports</h3><p>A weekly flower-aging system should help managers make decisions, not create another layer of administrative noise. A well-defined system should surface products approaching age thresholds, SKUs with weak sell-through, items with repeated markdowns, and inventory that no longer matches its intended price tier. Those products should be evaluated quickly and, when necessary, discontinued from future buys.</p><p>At minimum, retailers should track harvest date, package date, received date, use-by date where applicable, days on hand, units on hand, sell-through rate, gross margin, markdown history, and menu placement. The goal is not to perfect the perfect data system. The goal is to identify margin risk early enough to do something about it.</p><p>First-in, first-out is a good starting point, but it is not always enough. Stores also should use first-expired, first-out (FEFO) workflows because the first product received is not always closest to its use-by date. A more disciplined system considers age, velocity, and margin together.</p><h3>Promote before the product feels old</h3><p>Markdowns work best when they protect velocity, not when they rescue inventory. A preventive promotion at the right moment may preserve more margin than a clearance sale after a product has lost momentum.</p><p>This is another lesson from grocery. Produce managers use price reductions, display priority, and cross-merchandising while product still has appeal. The same thinking applies to flower. Feature a cultivar while its terpene profile still has a strong story. Use staff picks to call attention to products that need velocity. Bundle slower-moving flower with complementary items. Deploy loyalty offers to move inventory quietly instead of training the entire market to wait for discounts.</p><p>The timing matters. Once a product has crossed from “needs attention” to “must go,” the retailer has fewer options and less leverage.</p><p>Storage discipline should reinforce the same objective. Cool, dark, stable conditions; limited oxygen and light exposure; separate sample inventory; and regular package inspections all help protect the selling window. These practices are not new, but in a margin-compressed market they deserve renewed attention.</p><h3>Freshness is cash management</h3><p>Retailers cannot control wholesale volatility, price compression, or every shift in consumer preference. They can, however, control purchasing discipline, vendor expectations, tracking systems, storage conditions, and the timing of promotions.</p><p>This process should not depend on memory, staff habit, or a manager noticing old package dates during a slow shift. It should be proactively managed as a financial control.</p><p>In a market where every margin point matters, freshness is not just about delivering a better customer experience. It is about protecting cash flow, preserving trust, and making sure premium products do not become discounted inventory before their time.</p><p>By <a href="https://mgmagazine.com/author/andrew-iannelli/"><strong>Andrew Iannelli</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/stale-flower-is-a-margin-killer/">https://mgmagazine.com/retail-brands/retailing-merchandising/stale-flower-is-a-margin-killer/</a> on May 29th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=90b86c92fdcd" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/stale-flower-is-a-margin-killer-90b86c92fdcd">Stale Flower Is a Margin Killer</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Edibles Are Growing Up, and Manufacturing Needs to Catch Up]]></title>
            <link>https://medium.com/mg-magazine/edibles-are-growing-up-and-manufacturing-needs-to-catch-up-2fca4b2ddf9d?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/2fca4b2ddf9d</guid>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[manufacturing]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Mon, 25 May 2026 17:26:37 GMT</pubDate>
            <atom:updated>2026-05-25T17:26:37.391Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*C-bYSPGkotWYqzUB.jpg" /><figcaption><em>As the cannabis edibles market matures, consistency in gummy manufacturing has transitioned from a quality goal to a major competitive advantage. (Photo: Elsa Olofsson / Unsplash)</em></figcaption></figure><p>For years, the cannabis edibles category was a <a href="https://mgmagazine.com/products-innovation/new-product-development/bite-me-strangely-satisfying-cannabis-edibles/">creative playground</a> — a space where brands could experiment with flavor, texture, and effect, often operating like high-end craft kitchens.</p><p>Today, the “wild west” era of craft-scale production is hitting a wall. Behind the scenes, the category is growing up, and the growing pains are becoming expensive. With global edibles sales on track to <a href="https://www.custommarketinsights.com/report/cannabis-edibles-market/">surpass $55 billion</a> over the next decade, this is no longer a niche category; it is a high-stakes manufacturing race.</p><p>The brands that will be here in 2030 aren’t necessarily the ones with the flashiest packaging. They are the ones with the most disciplined production floors.</p><h3>The costly reality of gummy manufacturing variables</h3><p>Gummies have become the industry’s go-to format for a reason: They’re familiar and shelf-stable, and consumers love them for consistency. But what looks simple on a retail shelf is a technical masterpiece behind the curtain.</p><p>I’ve seen thousands of dollars worth of product turn into a sticky, unsalvageable mess because a room’s humidity dropped by 5 percent or a cook time was off by thirty seconds. In the early days, we called this the cost of doing business. Today, it’s a mistake that can sink a brand.</p><p>Gummies are one of the most technically sensitive products. Small changes in temperature, timing, or ingredient ratios can affect taste, of course, but more importantly they compromise dosing accuracy, clarity, and safety. These variables multiply as you scale.</p><h3>Scaling edibles: shifting from test kitchens to MSO production lines</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Dzq8eSbraYBXXZbb.jpg" /><figcaption><em>Behind the scenes, scaling up production from craft recipes to standardized industrial processes requires extreme precision to maintain accurate dosing. (Photo: Melt-to-Make)</em></figcaption></figure><p>In the early days, recipes evolved batch by batch. If the texture was slightly off, the lead cook adjusted on the fly. That intuitive approach works in a test kitchen, but it’s a liability on a multistate operator’s (MSO’s) production line.</p><p>There’s a common fear in our industry that standardization is the death of creativity. I argue the opposite. Standardization is the only way creativity survives at scale. A Michelin-star chef doesn’t reinvent the physics of a roux every night; they rely on a perfectly calibrated kitchen so they can focus on the artistry of the dish. Cannabis must adopt the same mindset. Growth depends on repeatability — not just great ideas, but systems that can execute those ideas consistently across five different states with five different crews.</p><h3>Formulations vs. equipment: identifying bottlenecks in edibles production</h3><p>One of the biggest misconceptions in edibles is that <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/automation-end-of-line-cannabis-manufacturing-packaging/">bottlenecks are caused by equipment</a> or staffing. In reality, the silent killer of margins is usually the formulation.</p><p>If your base system isn’t 100-percent stable, everything downstream suffers. Your production team spends more time “firefighting” than producing. The Friday afternoon panic, where a batch fails to set and a delivery deadline is missed, is almost always a failure of the system, not a person.</p><p>Consistency is no longer a quality goal; it is your most aggressive competitor.</p><p>Scaling requires a psychological shift: moving from a mindset of experimentation to one of control.</p><h3>The case for industrial standardization and pre-stabilized bases</h3><p>As the industry matures, we are seeing a shift toward semi-finished ingredient systems, a practice long used by the global food giants. Instead of rebuilding a gummy formulation from scratch for every batch, smart operators are using stabilized foundational components.</p><p>By standardizing the gummy base, manufacturers can:</p><ul><li><strong>Reduce cook times</strong> by up to 50 percent, immediately increasing throughput.</li><li><strong>Eliminate human error</strong> in the most volatile stages of the cook.</li><li><strong>Focus on differentiation</strong>, spending their energy on unique cannabinoids, terpenes, and flavors rather than worrying whether the gelatin will set.</li></ul><h3>Protecting margins and multistate brand consistency</h3><p>As markets expand, consistency is the baseline. If a consumer buys your gummy in Massachusetts and then again in Florida, and the texture or effect is different, you haven’t lost just a sale. You’ve also lost a brand advocate.</p><p>Beyond the consumer, there is the reality of margin pressure. Failed batches and extended development cycles are silent margin-killers. In a tightening market, the difference between a brand that scales and one that stalls is the ability to deliver the same product at scale, without sacrificing efficiency.</p><h3>The future of cannabis edibles: prioritizing execution over novelty</h3><p>The edibles category is entering a new phase defined less by novelty and more by execution. The “how” is now more important than the “what.” We have to stop thinking like chefs and start thinking like engineers. Edibles brands’ survival depends on building a process that can deliver a great product over and over again, no matter where or how it’s produced.</p><p>In this industry, consistency isn’t just a goal. It’s the ultimate competitive advantage.</p><p>By <a href="https://mgmagazine.com/author/sarah-mclaughlin/"><strong>Sarah McLaughlin, MS, RD</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/cannabis-gummy-manufacturing-standardization-scaling/">https://mgmagazine.com/products-innovation/manufacturing-processing/cannabis-gummy-manufacturing-standardization-scaling/</a> on May 22nd, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2fca4b2ddf9d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/edibles-are-growing-up-and-manufacturing-needs-to-catch-up-2fca4b2ddf9d">Edibles Are Growing Up, and Manufacturing Needs to Catch Up</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Federal Cannabis Contradiction]]></title>
            <link>https://medium.com/mg-magazine/the-federal-cannabis-contradiction-a0621a626095?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/a0621a626095</guid>
            <category><![CDATA[veterans]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[federal]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Wed, 20 May 2026 20:30:25 GMT</pubDate>
            <atom:updated>2026-05-20T20:30:25.827Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*YE-LfW3WhlpkPN6c.jpg" /><figcaption><em>Photo: Bumble Dee/ Shutterstock.com.</em></figcaption></figure><p>The same United States House of Representatives that voted to let Veterans Administration doctors help vets access medical cannabis also voted, nearly simultaneously, to block the federal rescheduling process that would make such access legally coherent. That is not mixed signals; it is a fractured federal posture. For the roughly 9 million veterans enrolled in VA healthcare, it lands with consequences that are anything but abstract.</p><p>On May 14, the House passed <a href="https://mast.house.gov/blog?ID=AB2F55DD-A4B8-4E3F-997C-F176C31605FE">an amendment</a> to the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act by voice vote. The amendment, co-sponsored by Representatives Brian Mast (R-FL), Dave Joyce (R-OH), and Dina Titus (D-NV), would, if enacted, prevent the VA from enforcing the provisions of <a href="https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=11394">Veterans Health Administration Directive 1315</a> that bar providers from helping veterans access state-approved medical cannabis programs. If signed into law, VA doctors will be able to sign the required forms.</p><p>One day earlier, the House Appropriations Committee passed <a href="https://appropriations.house.gov/sites/evo-subsites/republicans-appropriations.house.gov/files/evo-media-document/fy27-commerce-justice-science-and-related-agencies-subcommittee-mark.pdf">Section 591</a> of the FY2027 Commerce, Justice, Science, and Related Agencies Bill, 32–28. The text is spare but potent: “None of the funds appropriated under this Act or otherwise made available by this Act may be used [by the Department of Justice] to reschedule marijuana […] or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act.”</p><p>It’s a classic example of “what Congress giveth with one hand, Congress taketh away with the other.”</p><h3>Understanding VHA Directive 1315 and the cost of care</h3><p>To understand why the legislative simultaneity matters, one must understand exactly what Directive 1315 does — and what it costs veterans.</p><p>Under Directive 1315, revised July 2023, VA healthcare providers are “prohibited from recommending, making referrals to, completing forms or registering Veterans for participation in a State-approved marijuana program.” A VA doctor can ask a veteran about cannabis use. They can document it in the veteran’s medical file. They can discuss drug interactions. What they cannot do is sign the form a state’s medical program requires for enrollment. That requires a private physician.</p><p>Private cannabis evaluations typically cost $75 to $300, depending on state and visit type. Add state registration fees — as much as $150 in some states — and a new veteran patient may spend $150 to $500 just to legally access the plant. The VA covers prescription medications for enrolled veterans, but cannabis, by directive and federal law, is explicitly excluded. For veterans on fixed incomes, that financial wall is not an inconvenience. It is the gap between treatment and continued suffering.</p><p>The numbers give scale to those stakes. A March 2025 study found <a href="https://norml.org/news/2025/03/13/survey-nearly-half-of-military-veterans-use-cannabis-for-pain-relief/">40 percent of veterans with chronic pain reported using cannabis</a> to manage symptoms. Pain and mobility were cited as the primary reason for cannabis use by 81 percent of respondents. Another 62 percent cited sleep, and 43 percent cited PTSD or anxiety. A May 2025 <a href="https://www.news-medical.net/news/20250519/Study-reveals-high-rates-of-cannabis-use-disorder-in-older-US-veterans.aspx">Veterans Health Administration cohort study</a> found more than one in 10 veterans aged 65 to 84 had used cannabis in the past 30 days. More than 20 percent of veterans aged 18 to 44 report cannabis use. These are not recreational users gaming a policy gap. They are people who came home from recent foreign actions carrying injuries the VA has struggled to treat, paying out of pocket for relief their own providers cannot officially acknowledge.</p><h3>The Mast-Joyce-Titus amendment: what it changes (and what it doesn’t)</h3><p>The Mast-Joyce-Titus amendment would bar the VA from enforcing the form-completion prohibition of Directive 1315 in states where medical cannabis is legal. VA doctors could complete enrollment paperwork. Veterans could enter state programs through their own care team.</p><p>What it would not change: The VA still would not pay for approved medical cannabis products. Veterans would still pay out of pocket for the plant. Cannabis would remain prohibited on VA property.</p><p>Critically, since this is an appropriations rider, it must survive Senate consideration and conference committee negotiations. A similar measure cleared both chambers in mid-2025, then was stripped in conference before the FY2026 budget bill was signed into law. The version that became law in November 2025 <a href="https://norml.org/news/2025/11/13/federal-lawmakers-approve-military-funding-bill-denying-veterans-access-to-medical-cannabis/">omitted veterans’ medical cannabis access</a>. The current amendment has the shape of progress. It does not yet have the weight of law.</p><h3>Section 591: the legislative effort to block Schedule III</h3><p>Section 591 is, in some ways, the stranger story, because the committee’s action directly contradicts the Trump administration’s posture on rescheduling.</p><p>On December 18, 2025, President Trump <a href="https://mgmagazine.com/policy-regulation/trump-executive-order-cannabis-rescheduling-schedule-iii/">signed an executive order</a> directing the Attorney General to expedite rescheduling from Schedule I to Schedule III. On April 23, 2026, Acting Attorney General Todd Blanche followed through when he <a href="https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products">signed an order</a> placing marijuana products approved by the Food and Drug Administration as well as state-licensed medical marijuana products on Schedule III. At the same time, the Drug Enforcement Administration set June 29, 2026, as the start date for an administrative hearing to determine whether cannabis should move to Schedule III more broadly. Adult-use cannabis remains on Schedule I.</p><p>The executive branch was moving forward on reform. Then a Republican-led committee voted to stop progress.</p><p>Arguments marshaled for Section 591 leaned on public health concerns: high-potency products, <a href="https://mgmagazine.com/health-wellness/u-s-surgeon-general-issues-cannabis-advisory-for-pregnant-women-teens/">links to teen psychosis</a>, impaired driving, mixed messages to young people. There were procedural objections as well: The FDA has not formally found cannabis safe and effective, and the rescheduling order bypasses the randomized controlled trial standard DEA historically has required.</p><p>What Section 591 does not address is what passage of the bill as-is would do to the June 29 hearing. That administrative proceeding — the formal process that would determine the full scope of rescheduling — could be defunded before it begins if the provision passes into law. The Veterans of Foreign Wars called Trump’s December executive order a step that <a href="https://www.vfw.org/media-and-events/latest-releases/archives/2025/12/vfw-applauds-presidential-action-rescheduling-hemp-derived-products-for-treatments">“prioritizes science over stigma.”</a> The Iraq and Afghanistan Veterans of America <a href="https://iava.org/media/iava-applauds-executive-action-on-cannabis-rescheduling-calls-for-comprehensive-reform-to-support-veterans">applauded the therapeutic recognition</a> while noting that rescheduling alone doesn’t solve access, equity, or protection for veterans. Both organizations were watching the same reform take shape. Both are now watching a committee try to shut it down.</p><h3>Market impact: what the cannabis policy split means for operators and investors</h3><p>For operators, the immediate read is familiar: The regulatory environment remains contested. Blanche’s April order already has begun unwinding some 280E tax exposure for state-licensed medical operators. Section 591, if it becomes law, doesn’t reverse that order, but it does foreclose expansion of those benefits through the hearing process. Investors modeling full Schedule III economics should treat the committee vote as a material risk factor, not a procedural footnote.</p><p>For advocates, the pattern should be clarifying. The VA amendment passing by voice vote reflects genuine bipartisan consensus on the narrow question of whether VA doctors should be allowed to complete enrollment forms. What is also real is the same measure has been stripped in conference before, and the Senate has yet to act. Progress in one chamber is not the same as enacted law, and voice-voting for the VA amendment cost nothing. Nobody has to defend a pro-veterans vote in a tough primary election. Stripping the amendment in conference, where the votes are quiet and accountability is diffuse, costs nothing either.</p><p>For veterans — the roughly 9 million in VA healthcare who are living in <a href="https://www.publichealth.va.gov/marijuana.asp">the gap between what is legal and what they can access</a> — the calculus is unchanged today. Their doctors still cannot complete a form. The hearing that could change the federal framework is scheduled for June 29, contingent on a funding provision that may or may not survive.</p><h3>The next critical steps for federal cannabis policy</h3><h3>The legal conflict between Directive 1315 and the Blanche order</h3><p>The directive’s prohibition on provider participation in state cannabis programs rests on a specific legal foundation: cannabis’s Schedule I status under the Controlled Substances Act — no accepted medical use, highest abuse potential, the full framework. The Blanche order changed that foundation for state-licensed medical cannabis. Schedule III carries a different legal character entirely. The VA has not acknowledged this publicly, but the implication is uncomfortable for the department: It is now operating under a clinical prohibition whose statutory predicate the executive branch has formally abandoned. That’s not a political argument. It’s a structural one. Directive 1315 is an internal administrative document, not a statute. The VA Secretary can revise or rescind it without an act of Congress. The directive was last updated in July 2023, demonstrating the language moves when the department decides to move it. The Trump administration ordered rescheduling. If the VA declines to revisit 1315 in response, it will be the executive branch contradicting itself on its own policy.</p><p>A counterargument exists and deserves acknowledgment: Cannabis still lacks FDA approval for any specific clinical indication, which gives the VA independent grounds to maintain the directive’s restrictions regardless of schedule. That argument is weaker post-Blanche, but it is available to the department and likely to be invoked. What advocates should be pressing for — and what reporters should be asking — is whether the VA Secretary has been formally asked to review Directive 1315 in light of the rescheduling order, and what the answer was. The absence of that exchange on the public record is itself a signal.</p><h3>The Senate’s role in surviving the conference committee</h3><p>Whether the VA amendment survives into an enrolled bill is the near-term question, and the answer lies with the Senate and subsequent conference committee. A Senate companion bill would strengthen the Mast-Joyce-Titus amendment’s position substantially; its absence is a vulnerability.</p><h3>The fate of the June 29 rescheduling hearing</h3><p>If Section 591 does not survive into final law, the broader rescheduling process will proceed. If the section lands in a signed spending bill, the hearing’s legal and financial footing will be contested. The distance between those two outcomes is measured in conference committee votes.</p><p>Congress has not built a cannabis policy. It has built a contradiction and applied it to the people who can least afford to wait for the institution to sort itself out.</p><p>Originally published at <a href="https://mgmagazine.com/policy-regulation/the-federal-cannabis-contradiction/">https://mgmagazine.com/policy-regulation/the-federal-cannabis-contradiction/</a> on May 19th, 2026.</p><p>By <a href="https://mgmagazine.com/author/nora-whitfield/"><strong>Nora Whitfield</strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a0621a626095" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/the-federal-cannabis-contradiction-a0621a626095">The Federal Cannabis Contradiction</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[MJ Unpacked: Why Experience Trumps Price in Cannabis Retail]]></title>
            <link>https://medium.com/mg-magazine/mj-unpacked-why-experience-trumps-price-in-cannabis-retail-9e2ede6d92b0?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/9e2ede6d92b0</guid>
            <category><![CDATA[trade-show]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[conference]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Mon, 18 May 2026 22:21:03 GMT</pubDate>
            <atom:updated>2026-05-18T22:21:02.954Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*MUtvmEMdaI5Z-il1.jpg" /><figcaption><em>Photo: MJ Unpacked</em></figcaption></figure><p><strong>ATLANTIC CITY, NJ</strong> — <a href="https://mjunpacked.com/">MJ Unpacked</a>’s East Coast conference wrapped last weekend with a clear consensus across its panel discussions: Cannabis operators who build lasting brand-retailer partnerships aren’t competing on price. They’re competing on experience.</p><p>Panels at the Atlantic City event drew retailers, brand leaders, and operators who shared strategies for merchandising, delivery, loyalty, and customer experience.</p><h3>Meeting consumers where they are</h3><p>In competitive markets, the channel matters as much as the product. In New York, 75 percent of dispensary business comes through online orders or delivery, according to <a href="https://www.linkedin.com/in/carol-tyson/">Carol Tyson</a>, director of marketing for New York brand Jaunty. That means a customer’s first interaction with a brand is often a digital menu — not a budtender or a shelf display. “Messaging has to be absolutely consistent across the board to eliminate any confusion within the purchase decision of the customer,” Tyson said during the “Designing the Buy: How Cannabis Merchandising Drives Sales” panel.</p><p>Delivery customers behave differently from in-store shoppers, noted <a href="https://www.linkedin.com/in/mathewkrishnamachari/">Matt Krishnamachari</a>, founder and chief executive officer of California’s Purple Lotus Dispensary. They tend to spend more — they don’t have time to visit a physical store — and they expect professionalism to match. The challenge for operators is translating the in-store brand experience to a single driver at someone’s door.</p><p>Brand presence beyond the shelf matters equally. “The brands that do well in our stores support our events,” said <a href="https://www.linkedin.com/in/dharshcasi/">Dharsh Casinathen</a>, co-founder of Joy Leaf in New Jersey.</p><h3>Keep it simple</h3><p>Joy Leaf carries about 72 brands and just under 600 SKUs, but 70 percent of revenue comes from 30 percent of those SKUs. Casinathen structures her inventory in three tiers — value, premium, and new and exciting — each calibrated to a specific customer type. Rather than organizing products by category, she builds around what she calls “moments”: sleep, relaxation, social occasions. When the story is built around a customer’s life rather than a product spec, she said, it sells.</p><p>The same principle applies to brand messaging. Customers don’t need to understand <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/which-is-the-better-extraction-method-solvent-or-solventless/">extraction technology</a> or strain genetics. They need to know whether a product will meet their needs, and <a href="https://mgmagazine.com/business-strategy/human-resources-business-strategy/creating-the-perfect-budtender/">a well-trained budtender</a> is the critical link. Casinathen said a budtender should be able to answer four questions in 15 seconds:</p><ul><li>What is this product?</li><li>Who is it for?</li><li>How do I sell it?</li><li>Why is it best for this customer?</li></ul><h3>Avoiding the race to the bottom</h3><p>Price competition dominated the conversation across multiple panels — specifically, the dangers of relying on it.</p><p>“If we just keep racing to the bottom, what happens when we can’t use price as leverage?” asked <a href="https://www.linkedin.com/in/spencerbelz/">Spencer Belz</a>, chief operating officer for SunnyTien Dispensary in Atlantic City. “When we all have razor-thin margins, we can’t run big discounts and compete with our neighbors.”</p><p>Delivery customers don’t price-shop the way in-store customers sometimes do, Belz asserted. They’ve already committed to ordering and are paying for reliability. But inconsistent discounting can destroy trust faster than high prices will. A customer who sees a 30-percent discount online and finds it gone at the register isn’t just disappointed. They’re done. “That’s the story of loyalty,” he said. “The 80/20 rule still holds: 20 percent of your customers are driving 80 percent of your revenue. That group isn’t looking for the cheapest option. They’re looking for a place they can rely on.”</p><p>Krishnamachari framed <a href="https://mgmagazine.com/press-releases/data-signals-cannabis-market-stabilization-as-4-20-shifts-to-loyalty-driven-event/">the loyalty equation</a> in terms familiar to any consumer marketer: Nike and Coca-Cola don’t lead with price. They sell a lifestyle, a feeling, an identity. “We all want to spend money with people we like, companies we trust,” he said. “Once you resonate with that, the price tag isn’t going to matter so much.”</p><h3>Getting your house in order</h3><p>Brand resonance and merchandising strategy matter only if operations can back them up. Krishnamachari stressed that inventory, routing, team training, and technology must all be dialed in, and online, in-store, and delivery app listings must carry matching brand information, accurate inventory, and quality product photography. When a customer orders a product that turns out to be unavailable, they have just developed a trust problem with that retailer.</p><p>Casinathen’s starting point: Audit your digital menu as a first-time customer would. Is it easy to navigate? Are the categories correct? Are product photos current and consistent with what’s actually on the shelf? “That is the easiest fix we can make,” she said, “and it directly impacts sales.”</p><p>Technology that underperforms should be replaced, Belz said. <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/how-to-keep-cannabis-loyalty-programs-on-top/">Loyalty programs</a> that don’t track properly, inventory systems that don’t sync, and e-commerce platforms that add friction are liabilities in a market where consumers expect the kind of one-click convenience Amazon has made the gold standard. “If you’re not able to fully provide that level of service,” he said, “they’re going to find somebody else who can.”</p><h3>The bottom line</h3><p>Retail that works is an ecosystem. The brand, the retailer, the budtender, the delivery driver, the digital menu, the loyalty program — none of it is expendable, and none of it functions in isolation. When every element is aligned around the customer’s experience, the margin holds and trust compounds. When any piece breaks down, no discount is deep enough to cover the gap.</p><p>By <a href="https://mgmagazine.com/author/pam-chmiel/"><strong>Pam Chmiel</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/mj-unpacked-atlantic-city-retail-strategies/">https://mgmagazine.com/retail-brands/retailing-merchandising/mj-unpacked-atlantic-city-retail-strategies/</a> on May 14th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9e2ede6d92b0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/mj-unpacked-why-experience-trumps-price-in-cannabis-retail-9e2ede6d92b0">MJ Unpacked: Why Experience Trumps Price in Cannabis Retail</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Cannabis Must Embrace Data-driven Operations]]></title>
            <link>https://medium.com/mg-magazine/why-cannabis-must-embrace-data-driven-operations-166e49c7c0bd?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/166e49c7c0bd</guid>
            <category><![CDATA[business-strategy]]></category>
            <category><![CDATA[data]]></category>
            <category><![CDATA[operations]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Wed, 13 May 2026 17:39:29 GMT</pubDate>
            <atom:updated>2026-05-13T17:39:28.902Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*JyvNRFZeStzcMijR.png" /><figcaption><em>Image: mg Creative (Mixed Media)</em></figcaption></figure><p>The cannabis industry has undergone a remarkable transformation over the past decade. What began as a fragmented, largely informal ecosystem shaped by prohibition and fueled by passion has evolved into one of the fastest-growing regulated markets in the country. Today, operators are no longer simply cultivating and selling cannabis; they are <a href="https://mgmagazine.com/products-innovation/manufacturing-processing/scale-your-cannabis-company-like-a-pro-with-two-essential-tactics/">building scalable businesses</a> in an increasingly competitive, scrutinized, and sophisticated environment.</p><p>With that evolution comes a fundamental shift in how success is defined. The next phase of cannabis growth will not be driven by intuition alone, but by operational precision. Businesses that once relied on “feel” and experience must now embrace data, <a href="https://mgmagazine.com/retail-brands/retailing-merchandising/automation-is-standardizing-the-cannabis-industry/">standardization</a>, and compliance frameworks to remain viable. Between the pressures of scaling multistate operations, navigating complex regulations, and meeting rising consumer expectations, the contrast between patchwork processes and precision systems has never been starker or more consequential.</p><h3>The legacy of intuition</h3><p>The foundation of today’s cannabis industry was built by legacy cultivators whose ingenuity and craftsmanship carried the plant through decades of prohibition. These operators developed sophisticated growing techniques without access to formal research, institutional capital, or modern infrastructure. Their methods — hand-trimmed flower, closely monitored by sight, smell and touch — produced some of the most celebrated cannabis in the world.</p><p><a href="https://mgmagazine.com/sponsored/post-harvest-cannabis-quality/">Post-harvest practices</a> were equally hands-on. Techniques like jar curing and “burping” became industry standards, not because they were scalable, but because they worked within the constraints of the time. Environmental adjustments were made based on instinct rather than instrumentation. Quality was assessed subjectively, relying on the expertise of seasoned cultivators rather than quantifiable metrics.</p><p>These approaches reflect a deep respect for the plant and an intimate understanding of its nuances. But they also reveal inherent limitations. Without consistent data capture, repeatability becomes difficult and variability between batches increases significantly. As operations scale, these inconsistencies eventually lead to uneven product quality, inefficiencies and lost revenue opportunities.</p><h3>The complexity of scale</h3><p>The challenge has become more difficult in today’s commercial environment. Modern cannabis operators are managing multiple facilities, dozens or even hundreds of SKUs, and distribution across diverse regulatory markets. The complexity alone introduces risk. Without standardized processes and measurable controls, small deviations in cultivation, post-harvest handling, or storage can lead to significant downstream impacts: batch variability, product degradation, excess waste and, ultimately, brand erosion.</p><p>Scaling cannabis is not simply about producing more. It is about producing consistently. That requires a level of operational discipline that legacy methods on their own cannot reliably deliver. Today it is increasingly clear that controlled environments, documented standard operating procedures (SOPs), and real-time performance metrics are essential to maintaining both quality and margins.</p><p>At the same time, <a href="https://mgmagazine.com/business/legal-politics/cannabis-rescheduling-dea-middleman-catch/">regulatory expectations are intensifying</a>. As cannabis continues its march toward broader legalization and normalization, oversight is increasing in parallel. Operators should anticipate stricter testing requirements, more robust track-and-trace systems, and a growing alignment with <a href="https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/gmp">Good Manufacturing Practices</a> (GMP) and formal quality-assurance protocols.</p><p>In this environment, repeatability and documentation become crucial. It is no longer enough to produce a great batch once. Operators must be able to produce it the same way every time. Compliance often is viewed as a burden but, in reality, it provides a framework for operational excellence. The same systems that ensure regulatory adherence also enable better decision-making, improved efficiency, and reduced risk. In some cases, an operator’s license may depend on those characteristics.</p><h3>The role of modern technology</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*E6eytJWioiCIbJAK.jpg" /><figcaption><em>Illustration: mg Creative</em></figcaption></figure><p>Fortunately, technology is rapidly closing the gap between legacy practices and modern operational demands. Across the value chain, data-driven tools are transforming how cannabis businesses operate.</p><p>At retail, point-of-sale analytics and inventory management systems are enabling operators to better understand consumer behavior, optimize product mix, and refine pricing strategies. Data-driven merchandising allows retailers to tailor offerings to specific customer segments, improving both the shopping experience and overall revenue performance. Forecasting tools help reduce stockouts and overproduction, aligning supply more closely with demand.</p><p>In cultivation, <a href="https://mgmagazine.com/products-innovation/flower-cultivation/artificial-intelligence-in-the-grow/">integrated environmental control systems</a> are bringing new levels of precision to the grow environment. Advanced HVAC, lighting, and irrigation systems paired with sensors and software platforms allow operators to monitor and adjust conditions in real time. Data collection on yield, cannabinoid profiles, and plant health provides valuable insight that can be used to refine SOPs and improve consistency across harvests.</p><p>Post-harvest, long considered one of the most variable and least controlled stages of production, also is undergoing a transformation. Controlled drying, curing, and storage technologies are replacing inconsistent manual processes, thereby reducing reliance on subjective decision-making. These systems help preserve terpene profiles, stabilize moisture content, and deliver more uniform outcomes from batch to batch. Just as important, they generate data that can be integrated into broader operational analytics, creating a continuous feedback loop for improvement.</p><p>This shift toward precision is closely tied to the emergence of cannabis as a true consumer packaged good (CPG). Like food, beverages, and pharmaceutical products, cannabis increasingly is evaluated based on consistency, safety, and reliability. Consumers expect clearly labeled products, predictable effects, and a high level of quality assurance, regardless of where or when they make a purchase.</p><p>Meeting these expectations requires more than great genetics or skilled cultivation. It demands systems that can deliver a repeatable experience at scale. Data-driven operations enable that consistency, providing the foundation for strong, trustworthy brands. In a crowded market, consumer loyalty is built on not just novelty, but also reliability and the confidence that a product will perform the same way every time.</p><p>As the cannabis industry continues to mature, the path forward is not about replacing craftsmanship with automation, but about integrating the two. The knowledge and intuition developed by legacy operators remain invaluable. The goal is to augment that expertise with data and systems that enhance precision, reduce variability, and support scalability.</p><p>Embracing data, standardization, and compliance should not be seen as a departure from cannabis culture, but as its evolution. These tools allow operators to protect what makes their products special while ensuring they can deliver that experience consistently to a broader audience. In that sense, operational rigor becomes a boon to craftsmanship rather than a constraint.</p><h3>Defining the future</h3><p>Looking ahead, <a href="https://mgmagazine.com/policy-regulation/cannabis-schedule-iii-impact-280e-analysis/">federal rescheduling</a> could further accelerate this shift, bringing increased oversight and higher standards across the industry. Operators who already have invested in data-driven systems and process control will be better positioned to adapt, while those relying on patchwork methods may struggle to keep pace.</p><p>The future of cannabis will be defined by those who can balance art and science and honor the plant’s legacy while embracing the discipline required to scale the industry responsibly. Precision is no longer optional. It is the foundation for trust, the driver of efficiency, and the key to sustainable growth in the next era.</p><p>By <a href="https://mgmagazine.com/author/ed-wells/"><strong>Ed Wells</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/business-strategy/operations-supply-chain/cannabis-data-driven-operations/">https://mgmagazine.com/business-strategy/operations-supply-chain/cannabis-data-driven-operations/</a> on May 11th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=166e49c7c0bd" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/why-cannabis-must-embrace-data-driven-operations-166e49c7c0bd">Why Cannabis Must Embrace Data-driven Operations</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Schedule III Reality Check: Tax Relief, Regulatory Gaps, and Hype Risk]]></title>
            <link>https://medium.com/mg-magazine/schedule-iii-reality-check-tax-relief-regulatory-gaps-and-hype-risk-18233cd6dc02?source=rss----a3e9cdb23cde---4</link>
            <guid isPermaLink="false">https://medium.com/p/18233cd6dc02</guid>
            <category><![CDATA[schedule-iii]]></category>
            <category><![CDATA[taxes]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannabis-journalism]]></category>
            <category><![CDATA[cannabis-industry]]></category>
            <dc:creator><![CDATA[mg Magazine]]></dc:creator>
            <pubDate>Wed, 29 Apr 2026 19:28:07 GMT</pubDate>
            <atom:updated>2026-04-29T19:28:06.985Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/696/0*NgprQ_1HSAx4Ftq1.png" /><figcaption><em>Illustration: mg Creative / Midjourney</em></figcaption></figure><p>Schedule III is real progress. It is also not the clean federal reset for which many, if not most, cannabis operators have spent years hoping.</p><p>That distinction matters now because the industry finally has a tangible federal shift to work with, but it also has a new round of hype risk. If operators misread what changed, they may make bad decisions about taxes, structure, capital planning, and compliance.</p><p>The clearest way to understand the moment is this: <strong>Schedule III changes some important business math, especially for qualifying medical marijuana operators, but it does not turn state cannabis into a normal national industry overnight.</strong></p><h3>Section 280E: the $700 million tax relief opportunity</h3><p>The <a href="https://mgmagazine.com/policy-regulation/federal-policy/cannabis-rescheduling-dea-middleman-catch/">April 23 federal order</a> reclassifying cannabis is narrower than the broadest headlines suggest. According to the Justice Department, the action immediately places two cannabis categories into Schedule III: FDA-approved products containing marijuana, and marijuana products subject to a qualifying state-issued medical marijuana operating license. At the same time, federal officials terminated <a href="https://mgmagazine.com/cannabis-news/dea-judge-hits-pause-on-cannabis-rescheduling/">Biden-era rescheduling proceedings</a> and launched a new hearing process to consider broader rescheduling, which could sweep adult-use products onto Schedule III at some future date.</p><p>That is significant. But it is not the same thing as declaring “cannabis is now Schedule III.”</p><p>For operators, the biggest practical change is tax treatment.</p><p>For years, one of the industry’s most punishing federal burdens has been <a href="https://www.congress.gov/crs-product/R46709">Internal Revenue Code Section 280E</a>, the tax rule that blocks businesses trafficking in Schedule I or II substances from deducting ordinary operating expenses. That is why cannabis companies have spent so much time talking about distorted effective tax rates, trapped cash flow, and business models built around surviving an abnormal tax structure.</p><p>“The most commercially meaningful component is the treatment of Section 280E,” according to Terry Mendez, chief executive officer at Safe Harbor Financial. “For qualifying state-licensed medical operators, the order removes the disallowance of standard business deductions, because 280E applies only to Schedule I or II substances. Historically, this provision has driven effective federal tax rates as high as 70 percent or more, materially constraining cash flow and distorting financial performance.”</p><p>For qualifying medical marijuana businesses, Schedule III changes that equation. If the product or activity falls within the newly covered medical lane, ordinary business deductions are no longer blocked by 280E. That is why rescheduling matters in real dollars, not just in symbolism. Rent, payroll, marketing, and other normal business expenses matter a lot more when operators can deduct them.</p><p>For some companies, especially multistate operators (MSOs) with meaningful medical exposure, that could materially improve cash flow and planning flexibility. A 2023 analysis by Viridian Capital Advisors suggested the elimination of 280E restrictions could save the twelve largest MSOs a combined <a href="https://mgmagazine.com/cannabis-news/analysis-eliminating-280e-could-save-12-msos-700-million-annually/">$700 million or more annually</a> in federal taxes. That figure likely is larger now.</p><p>“Removing 280E will materially improve after-tax cash flow for many operators,” said Darren Gleeman, managing partner at MBO Ventures. “That matters because valuation is driven by sustainable, normalized cash flow. When taxes stop consuming a large portion of operating income, free cash flow becomes more comparable to other regulated industries. That alone can support higher valuations by improving debt capacity, refinancing options, and overall exit flexibility.”</p><p>But this is where the industry needs discipline.</p><h3>Federal oversight: regulation vs. legalization</h3><p>Reclassifying cannabis from Schedule I to Schedule III does not mean every cannabis operator suddenly gets federal tax relief. The April 23 order does not broadly cover adult-use cannabis. If a business is operating in recreational markets, or in a mixed environment where medical and adult-use revenue overlap, the easy headline version of “280E is over” is too sloppy to rely on. The real answer is more conditional, and companies will need tax guidance, careful recordkeeping, and probably a much stricter line between covered and non-covered activity than some operators would prefer.</p><p>That is also why rescheduling should be understood as a major regulatory step toward federal <em>regulation</em> but not yet anywhere near federal <em>legalization</em>.</p><p>Cannabis remains a controlled substance under <a href="https://www.dea.gov/drug-information/csa">federal law</a>. State programs still govern the day-to-day rules by which operators live. Licensing, testing, labeling, packaging, marketing limits, security requirements, and state enforcement risk do not disappear because part of the industry moved to Schedule III.</p><p>The same goes for adult-use commerce. The order does not convert state recreational markets into fully federally lawful trade. It does not automatically open interstate cannabis shipping. It does not erase the structural reality that most operators are still functioning inside state-by-state systems that were built for containment, not national scale.</p><p>“This is a partial measure, not full reform,” NewLake Capital Partners CEO Anthony Coniglio warned. “The order does not extend to adult-use cannabis, does not legalize marijuana federally, and does not resolve the industry’s banking challenges. The broader rescheduling proceeding remains critically important.”</p><h3>Banking: why the needle moves slowly</h3><p>Banking is one area where reform remains crucial.</p><p>Schedule III may reduce some perceived federal risk around cannabis, and that could improve the tone of banking conversations over time. But it does not automatically rewrite every <a href="https://mgmagazine.com/business-strategy/operations-supply-chain/cannabis-cash-management-banking-relationships/">compliance obligation financial institutions face</a>. It also does not guarantee that lenders, payment providers, or insurers will suddenly treat the whole sector like any other consumer-packaged-goods business. Access may improve, but “improved” is not the same as “solved.”</p><p>“The order begins to formalize a federal pathway for medical cannabis within an established regulatory framework, including DEA registration, reporting, and compliance requirements aligned with Schedule III substances,” said FundCanna CEO Adam Stettner. “This introduces a higher bar for operational discipline while signaling to institutional capital that parts of the cannabis market are becoming more standardized and financeable. The industry’s core challenges persist, however. Operators will continue to face constrained access to capital, fragmented regulatory regimes, and ongoing cash-flow pressure across the supply chain.”</p><h3>Strategic gains: expanding medical research and credibility</h3><p>Research, on the other hand, will benefit from genuine strategic value beyond tax relief. Rescheduling gives the federal government a more coherent basis for expanded medical research and a more realistic posture toward marijuana’s accepted medical use. That matters for product development, physician engagement, and the long-term credibility of regulated medical programs. It may not deliver instant commercial payoff for every operator, but it does move the federal conversation closer to something that resembles a workable medical framework instead of a permanent contradiction.</p><p>Even there, though, operators should keep expectations in check. A more research-friendly environment does not instantly create Food and Drug Administration approval pathways for existing state-market products, and it does not make every current medical program federally simple. It creates a better lane, but not a frictionless one.</p><p>The other key point is operational.</p><p>Federal relief is arriving with federal structure. Qualifying medical operators are being pulled into a more formal registration and oversight framework. For serious businesses, that may be an acceptable trade. But it also means compliance work, registration timing, documentation, and process changes need attention now.</p><p>According to Paula Savchenko, Esq., founding partner of PS Law Group, “Schedule III status aligns federal law more closely with how cannabis is actually used in medical practice, research, and regulated markets across the country. This shift opens the door to expanded clinical research, clearer regulatory pathways, and a more rational national framework.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*IjzItgMQ_DfFnJAf.png" /><figcaption><em>Schedule III may offer relief, but the path forward remains complex. (Illustration: mg Creative / Midjourney)</em></figcaption></figure><h3>The takeaway</h3><p>So what should cannabis companies take from this?</p><p>First, treat Schedule III as real, but specific. This is not a vibes event. It is a classification event with narrow legal edges that matter.</p><p>Second, focus on where the financial impact is most immediate. For qualifying medical operators, 280E relief is the headline consequence because it can change margins, planning, and capital allocation quickly.</p><p>Third, do not confuse medical progress with universal industry relief. Adult-use operators still face major federal limitations. Mixed operators have important unanswered questions. Interstate commerce remains constrained. Banking remains incomplete. State compliance is still fully alive.</p><p>Finally, watch what comes next. The June hearing process on broader rescheduling matters. IRS guidance matters. The way regulators treat hybrid medical and adult-use businesses matters. And the market’s response matters too, because investors and operators now will have to separate companies with real exposure to Schedule III upside from those merely borrowing the narrative. That may be the most important takeaway of all.</p><p>In addition, rescheduling almost certainly will be challenged in court. On the same day Acting Attorney General Todd Blanche signed the rescheduling order, anti-legalization crusader Smart Approaches to Marijuana vowed <a href="https://www.cnn.com/2026/04/23/politics/justice-department-reclassify-marijuana">“immediate legal action”</a> to prevent order from taking effect. Multiple legal analysts have flagged the <a href="https://www.jurist.org/news/2026/04/us-reschedules-medical-cannabis-to-schedule-iii-easing-federal-restrictions/">unusual legal mechanism</a> Blanche relied upon to accomplish rescheduling as a potential vulnerability in the action.</p><p>Schedule III changes something meaningful. It does not change everything. For cannabis businesses, it is still a very big deal. But the winners in the next phase probably will be the operators who understand the limits as clearly as the opportunity.</p><p>By <a href="https://mgmagazine.com/author/andrew-iannelli/"><strong>Andrew Iannelli</strong></a></p><p>Originally published at <a href="https://mgmagazine.com/policy-regulation/cannabis-schedule-iii-impact-280e-analysis/">https://mgmagazine.com/policy-regulation/cannabis-schedule-iii-impact-280e-analysis/</a> on April 27th, 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=18233cd6dc02" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mg-magazine/schedule-iii-reality-check-tax-relief-regulatory-gaps-and-hype-risk-18233cd6dc02">Schedule III Reality Check: Tax Relief, Regulatory Gaps, and Hype Risk</a> was originally published in <a href="https://medium.com/mg-magazine">mg Magazine</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>